2006 Edition

Order a copy of the 2006 Edition of The Guide for $795 by contacting Alyssa Stern or calling (617) 367-1400.

Table of Contents

CEO Conversations

     Josh Boger – Vertex Pharmaceuticals
     Deborah Dunsire – Millennium Pharmaceuticals
     John Maraganore – Alnylam Pharmaceuticals
     Henri Termeer – Genzyme Corporation
     Richard Pops – Alkermes
     Daniel Vasella – Novartis AG
     Timothy Surgenor – Cyberkinetics Neurotechnology Systems
     Harry Penner, Jr. – Marinus Pharmaceuticals
     John Santini, Jr. – MicroCHIPS
     John Abele – Boston Scientific

Money
      Venture Capital Perspectives
         Dana Callow – Boston Millenia Partners
         Bob Higgins – Highland Capital Partners
         Jean-Francois Formela – Atlas Venture
         Ansbert Gadicke – MPM Capital
         Terry McGuire – Polaris Venture Partners
         Jean George – Advanced Technology Ventures
         Rob Bettigole – Elm Street Ventures
     Sources of Funding for N.E. Life Sciences Companies (2000 – 2005)
     Mind the Gap:  Addressing Biotech’s Early-Stage Funding Problem
     Does Innovation Pay?  Examining Trends in Early-Stage Investing
     N.E. Biotech’s 10 Biggest Funding Rounds of 2005
     The New Rules of Mergers & Acquisitions
     The IPO Market:  Companies Seek Other Options, While 
        Hoping for  a Biotech Renaissance on Wall Street
     The Most Active New England Life Sciences Investors of the 
        Past Decade
     New England VC Investments by State
     New England Venture-Backed IPOs:  The Last Five Years

Research
      New Frontiers:  New England ’s Top Academic Research Centers
     Stem Cell Research:  A New England Overview
     Big Pharma:  N.E.’s Major Pharmaceutical Sites

Influence
      The 25 Most Influential People in New England Life Sciences

Policy
      Sustaining a Healthy Medical Devices Ecosystem in Massachusetts
     Medical Devices in New England:  Trends and Analysis
     The View from the Capitol:  Stem Cells, Patents, and 
        Healthcare Costs
     Maintaining Leadership in the Life Sciences
     The State of Biotech in Connecticut  

History
      Life Sciences Innovation in Boston: The Greatest Hits

Expert Advice (from our underwriters)
      The Medicare Modernization Act:  Questions and Answers 
        TGN1412:  The Implications for Phase I Clinical Trials
     Personalized Medicine:  Legal, IP, and Other Implications
     Leadership in Life Sciences:  Questions and Answers
     The Benefits of Outsourcing Major Facility Project Management